Editorial
You have free access to this content
Allergic inflammation: focus on eosinophils
- Hans-Uwe Simon
Article first published online: 15 JUL 2013
DOI: 10.1111/all.12231
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
- Abstract
- Article
- References
- Cited By
In allergic diseases, such as atopic dermatitis [1], bronchial asthma [2, 3], rhinosinusitis [4], or eosinophilic esophagitis [5], eosinophil numbers are usually increased. Therefore, the physiological and pathological roles of eosinophils remain a hot research topic. Recent progress in the understanding of eosinophil biology includes recognizing the capacity of eosinophils to generate different functional subsets under in vivo inflammatory conditions [6], as well as extracellular DNA-containing structures able to bind and kill bacteria [7, 8]. Furthermore, new pathogenetic insights reveal a molecular link between organismal metabolism and eosinophilic inflammation [9].
The molecular interactions between mast cells and eosinophils in allergic inflammatory responses have evoked an increasing research interest [10, 11]. The activation of eosinophils may result in tissue damage; therefore, inhibition of eosinophil effector functions is an important therapeutic strategy in eosinophilic disorders [12]. Interestingly, CRTH2 antagonists have been demonstrated to exhibit anti-eosinophilic activities in allergic rhinitis [13] and eosinophilic esophagitis [14]. But how can the anti-eosinophilic activity of a given drug be monitored? The results of a recent study suggest that, although reduced blood eosinophil numbers may reflect an anti-eosinophilic efficacy, they do not necessarily indicate a reduced eosinophilic inflammation [15]. Thus, the search for and testing of eosinophil biomarkers remain subjects of intense investigation [16].
In this issue of Allergy, several original articles report interesting new findings with implications for the diagnosis and treatment of eosinophilic diseases. Simon et al. demonstrate that adult patients suffering from eosinophilic esophagitis are frequently sensitized towardCandida albicans [17]. It is possible that such patients would benefit from antimycotic therapy. Muniz-Junqueira et al. describe morphological changes in eosinophils that correlate with the severity of asthma exacerbations in children [18]. Ueki et al. observed that retinoic acids increase the functional expression of eotaxin receptors, suggesting that vitamin A derivatives could play an important role in the tissue accumulation of eosinophils [19]. Moreover, the molecular events of the eotaxin receptor-mediated signaling pathway have been investigated by Shamri et al., and the reported data are likely relevant for both host defense and immunopathology [20]. Gleich et al. reviewed the current opinion with respect to the consequences of eosinophil-depleting treatments [21], and the data collected appear to be of great interest, particularly, because several anti-eosinophilic therapies are still in development.
Taken together, research in the field of eosinophilic diseases continues to be promising. Indeed, several new therapeutic approaches to different allergic conditions have also recently been reported in the Journal [22-24]. In spite of this progress, the role of the eosinophil in physiology and disease remains a subject for further research.
Acknowledgement
Work in the laboratory of HUS is supported by the Swiss National Science Foundation and Allergie-Stiftung Ulrich Müller-Gierok, Bern, Switzerland.
Conflict of interest
The author declares no conflict of interest.
References
- 1Novak N, Simon D. Atopic dermatitis – from new pathophysiologic insights to individualized therapy. Allergy 2011;66:830–839.
- 2Hoskins A, Roberts JL II, Milne G, Choi L, Dworski R. Natural-source d-a-tocopheryl acetate inhibits oxidant stress and modulates atopic asthma in humans in vivo. Allergy 2012;67:676–682.
- 3Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy 2012;67:835–846.
- 4Pezato R, Swierczynska-Krepa M, Nizankowska-Mogilnicka E, Derycke L, Bachert C, Pérez-Novo CA. Role of imbalance of eicosanoid pathways and staphylococcal superantigens in chronic rhinosinusitis. Allergy 2012;67:1347–1356.
- 5Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012;67:477–490.
- 6Roth N, Städtler S, Lemann M, Hösli S, Simon HU, Simon D. Distinct eosinophil cytokine expression patterns in skin diseases – the possible existence of functionally different eosinophil subpopulations. Allergy 2011;66:1477–1486.
- 7Morshed M, Yousefi S, Stöckle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 2012;67:1127–1137.
- 8Simon D, Simon HU, Yousefi S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy2013;68:409–416.
- 9Dietze J, Böcking C, Heverhagen JT, Voelker MN, Renz H. Obesity lowers the threshold of allergic sensitization and augments airway eosinophilia in a mouse model of asthma. Allergy 2012;67:1519–1529.
- 10Elishmereni M, Alenius HT, Bradding P, Mizrahi S, Shikotra A, Minai-Fleminger Y et al. Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro. Allergy 2011;66:376–385.
- 11Elishmereni M, Bachelet I, Nissim Ben Efraim AH, Mankuta D, Levi-Schaffer F. Interacting mast cells and eosinophils acquire an enhanced activation state in vitro. Allergy 2013;68:171–179.
- 12Nissim Ben Efraim AH, Karra L, Ben-Zimra M, Levi-Schaffer F. The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosinophils. Allergy 2013;68:397–401.
- 13Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Collins LP, Hunter MG et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy2012;67:1572–1579.
- 14Straumann A, Hoesli S, Bussmann Ch, Stuck M, Perkins M, Collins LP et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68:375–385.
- 15Ullmann N, Bossley CJ, Fleming L, Silvestri M, Bush A, Saglani S. Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma. Allergy 2013;68:402–406.
- 16Khoury P, Zagallo P, Talar-Williams C, Santos CS, Dinerman E, Holland NC et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 2012;67:1149–1156.
- 17Simon D, Straumann A, Dahinden C, Simon H-U. Frequent sensitization to Candida albicans and profilins in adult eosinophilic esophagitis. Allergy 2013;68:945–948.
- 18Muniz-Junqueira MI, Barbosa-Marques SM, Junqueira LF Jr. Morphological changes in eosinophils are reliable markers of the severity of an acute asthma exacerbation in children. Allergy 2013;68:911–920.
- 19Ueki S, Nishikawa J, Yamauchi Y, Konno Y, Tamaki M, Itoga M et al. Retinoid acids up-regulate functional eosinophil-driving receptor CCR3. Allergy 2013;68:953–956.
- 20Shamri R, Young KM, Weller PF. PI3K, ERK, p38 MAPK and integrins regulate CCR-mediated secretion of mouse and human eosinophil-associated RNases. Allergy 2013;68:880–889.
- 21Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy 2013;68:829–835.
- 22Sharma SK, Almeida FA, Kierstein S, Hortobagyi L, Lin T, Larkin A et al. Systemic FasL neutralization increases eosinophilic inflammation in a mouse model of asthma. Allergy 2012;67:328–335.
- 23Lieberman JA, Morotti RA, Konstantinou GN, Yershov O, Chehade M. Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort. Allergy 2012;67:1299–1307.
- 24Sandell J, Hedman J, Saarinen K, Haahtela T. Salt chamber treatment is ineffective in treating eosinophilic inflammation in asthma.Allergy 2013;68:125–127.
